ArticleVaccines2025
Novel sACE2-Anti-CD16VHH Fusion Protein Surreptitiously Inhibits SARS-CoV-2 Variant Spike Proteins and Macrophage Cytokines, and Activates Natural Killer Cell Cytotoxicity.
Abdolkarim Sheikhi, Leili Baghaie, Fatemeh Rahbarizadeh, Pooria Safarzadeh Kozani, Cobra Moradian, Mohammadreza Davidi, Narges Baharifar, Golnaz Kaboli, Mehdi Sheikhi, Yunfan Li and 5 more
Abstract read
In one paragraphArticle in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Abdolkarim SheikhiDepartment of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0002-3559-5548 Leili BaghaieDepartment of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0009-0000-7135-2570 Fatemeh RahbarizadehDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran.
Pooria Safarzadeh KozaniDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran.ORCID 0000-0002-9901-7851 Cobra MoradianDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran.ORCID 0000-0002-3948-4642 Mohammadreza DavidiFaculty of Medicine, Kazeroon Azad University, Kazeroon 14778-93855, Iran.
Narges BaharifarDepartment of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful 64616-43993, Iran.
Golnaz KaboliDepartment of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful 64616-43993, Iran.
Mehdi SheikhiFaculty of Medicine, Kazeroon Azad University, Kazeroon 14778-93855, Iran.
Yunfan LiFaculty of Arts and Science, Queen's University, Kingston, ON K7L 3N9, Canada.
William W HarlessENCYT Technologies Inc., Membertou, NS B1S 0H1, Canada.
Myron R SzewczukDepartment of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0001-8471-5481 Funding
Natural Sciences and Engineering Research Council of Canada (NSERC), RGPIN #388697
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19immunotherapysACE2-AntiCD16VHHSARS-CoV-2
Identifiers
PMID40006745
PMCPMC11860277
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390